2007
DOI: 10.1016/j.diabres.2007.01.017
|View full text |Cite
|
Sign up to set email alerts
|

Angiotensin receptor blockade in diabetic renal disease—Focus on candesartan

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
6
0

Year Published

2007
2007
2024
2024

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 11 publications
(6 citation statements)
references
References 45 publications
0
6
0
Order By: Relevance
“…Angiotensin II type 1 (AT 1 ) receptor blockers (ARBs) were reported to reduce inflammation in diabetic rat cardiac myocytes, reduce neointimal formation, decrease smooth cell proliferation via a variety of mechanisms including reduced oxidative stress, improving endothelial dysfunction, etc. [20][21][22][23]. Clinical studies have suggested that treatment with candesartan lead to decreased plasma levels of Creactive protein (CRP), TNF-α, IL-6, MCP-1, sICAM-1, and sVAM-1 in patients with mild to moderate chronic heart failure and hypertension [19,22,[24][25][26].…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Angiotensin II type 1 (AT 1 ) receptor blockers (ARBs) were reported to reduce inflammation in diabetic rat cardiac myocytes, reduce neointimal formation, decrease smooth cell proliferation via a variety of mechanisms including reduced oxidative stress, improving endothelial dysfunction, etc. [20][21][22][23]. Clinical studies have suggested that treatment with candesartan lead to decreased plasma levels of Creactive protein (CRP), TNF-α, IL-6, MCP-1, sICAM-1, and sVAM-1 in patients with mild to moderate chronic heart failure and hypertension [19,22,[24][25][26].…”
Section: Discussionmentioning
confidence: 99%
“…Angiotensin II type 1 (AT 1 ) receptor blockers (ARBs) like candesartan prevent cerebrovascular events and also help reduce progression of coronary heart diseases [15][16][17]. Candesartan (ARBs) is widely used for the treatment of high blood pressure [18], management of chronic heart failure [19], diabetic nephropathy [20], reverse endothelial dysfunction [21], and attenuate oxidative stress [22]. Candesartan has been reported to have antiatherosclerotic effects such as reducing neointimal formation in rats [23] and diminishing vascular inflammation [24][25][26].…”
Section: Introductionmentioning
confidence: 99%
“…Even if in the case of pharmaceuticals, the term "stability" is usually correlated with the loss of the active pharmaceutical ingredient from formulation, and "solid-state stability" can also designate the response of an API or a pharmaceutical formulation to thermal stress. However, in both cases, the decomposition of the API due to chemical processes or even physical transitions (phase transitions such as polymorphism and crystallization) in the presence of excipients dictates Acting in a dose-dependent manner, candesartan can be used in several pathologies such as essential arterial hypertension [5], ventricular hypertrophy [6], heart failure [7], diabetic nephropathy, [8] retinopathy [9], myocardial infarction [10], endothelial dysfunction [6,11], prehypertension [12], the prevention of atrial fibrillation [13], migraine prophylaxis [14], and stroke [15]. Recently, it has been shown to ameliorate brain inflammation associated with Alzheimer's disease [16] and to induce neuroprotective effects in patients suffering from Parkinson's disease [17].…”
Section: Introductionmentioning
confidence: 99%
“…This indicates that there may be a benefit for renoprotection in candesartan over ACE inhibitor therapy. In patients with diabetic nephropathy with varying degrees of albuminuria, treatment with candesartan 8-32 mg daily reduced UAE by up to 60% and, in combination with an ACE inhibitor, produced 25-35% greater reductions in UAE than treatment with ACE inhibitor monotherapy (80).…”
Section: Treatment Approaches For Microalbuminuria In Patients With Hmentioning
confidence: 98%